Importantly, it could work for all CF patients, whereas Vertex Pharmaceuticals' medicines target only those with certain ...

As drugmakers strive to fine tune the delivery of their medications for better convenience and patient adherence, Halozyme is putting a recent acquisition in the space to work, thanks to a new tie- | ...

Vertex Pharmaceuticals (VRTX) ended the recent trading session at $430.50, demonstrating a -1.06% change from the preceding day's closing price. The stock fell short of the S&P 500, which registered a ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

As growth in Vertex's cystic fibrosis portfolio buoys the company amid the launch of gene therapy Casgevy, the company is feeling confident enough to boost its revenue outlook for the year. After ...

Vertex Pharmaceuticals remains the leader in cystic fibrosis but is now executing a tangible diversification into pain, renal ...

"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions ...

Vertex is a leader in the billion-dollar cystic fibrosis treatment market. The company recently expanded beyond this specialty area with a newly approved blood disorder therapy. Vertex's plans to ...

Editor's Note: Vertex is a WBUR underwriter but has no role in editorial decisions. Vertex Pharmaceuticals is one of Massachusetts' oldest, largest and most successful biotech companies. Fifteen ...

View Vertex, Inc. Class A VERX stock quote prices, financial information, real-time forecasts, and company news from CNN.